Can Pharmaceutical Excipients Drive Profitable Growth in the Market?
The pharmaceutical excipients market is experiencing significant growth and is projected to continue expanding in the coming years. A recent report by MarketsandMarkets™ reveals that the market's revenue was estimated to be worth $10.0 billion in 2023 and is expected to reach $13.9 billion by 2028, with a compound annual growth rate (CAGR) of 6.8% during the forecast period.
Several key factors are contributing to this growth. Firstly, there is an increasing demand for generic drugs and pharmaceutical products, which is driving the need for pharmaceutical excipients. These excipients play a crucial role in drug formulation and delivery, ensuring the safety, stability, and effectiveness of medications.
Secondly, there has been a rise in research and development (R&D) investments for the development of novel excipients. Pharmaceutical companies are actively exploring new excipient options to enhance drug formulations and improve patient outcomes. This focus on innovation is opening up opportunities for excipient manufacturers to provide customized solutions to pharmaceutical companies through collaborations and partnerships.
Moreover, the market is witnessing a growing emphasis on patient-centric formulations. There is a shift towards developing dosage forms that are more patient-friendly, such as orally disintegrating tablets and modified-release formulations. These formulations require specialized excipients to achieve the desired drug release profiles, taste masking, and ease of administration.
The market dynamics present both opportunities and challenges. On the one hand, there is a rising demand for functional and multifunctional pharmaceutical excipients. These excipients offer added functionalities, such as improved drug solubility, controlled release, and enhanced stability. They cater to the evolving needs of the pharmaceutical industry and contribute to the development of advanced drug delivery systems.
On the other hand, the industry faces challenges in the form of stringent regulatory requirements. The pharmaceutical excipients market operates in a highly regulated environment, with strict quality and safety standards. Compliance with these regulations can be costly and time-consuming for excipient manufacturers.
In terms of regional growth, the Asia Pacific region is expected to lead the market expansion. Factors such as low labor and manufacturing costs in countries like China and India have attracted significant investments from pharmaceutical giants. Additionally, the prevalence of lifestyle-related and age-related diseases, rising disposable income, and government initiatives to improve healthcare infrastructure are fueling the demand for pharmaceutical excipients in the region.
Key players in the pharmaceutical excipients industry include International Flavors & Fragrances Inc., Ashland Inc., Evonik Industries AG, BASF SE, Kerry Group Plc, Roquette Frères, Merck KgaA, Associated British Foods Plc, ADM, and Wacker Chemie AG, among others. These companies are actively involved in product development and innovation to meet the evolving needs of the market.
In conclusion, the pharmaceutical excipients market is poised for profitable growth, driven by factors such as the increasing demand for generic drugs, R&D investments, and the focus on patient-centric formulations. While challenges exist in terms of regulatory requirements, the market presents opportunities for the development of functional and multifunctional excipients. With the Asia Pacific region emerging as a key growth market, excipient manufacturers are well-positioned to capitalize on the expanding pharmaceutical industry's needs.
Looking for chemical products? Let suppliers reach out to you!
2026-07-17
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Sun Pharma’s Winning Formula: Precision Over Expansion
-
U.S. API Dependence Turns Pharmaceutical Ingredients Into a National Security Issue
-
Pharma Tariff Risk Pushes Global Drugmakers to Rebuild U.S. Supply Chains
-
Emcure Seals Exclusive Deal for Sanofi’s Oral Diabetes Brands Millions of Indian Patients to Benefit
-
After Semaglutide Patent Expiry in India, the Price System Has Been Restructured as More Than 40 Drugmakers Enter the Competition
-
West Asia’s Conflict Is Testing the Hidden Fragility of Pharma Trade
-
South Africa Wants Lenacapavir at Home, Not Just Imported
-
China’s Approval of Pfizer’s GLP-1 Drug Signals a Sharper Obesity Race
-
A Cold-Chain Crackdown in Delhi Sends a Much Bigger Message
-
Affordable GLP-1s Could Rewrite the Global Obesity Market
Recommend Reading
-
Sun Pharma Halts US Expansion Amid 25 Percent Tariff Threat Net Profit Drops 20 Percent
-
Mounjaro Reduces Heart Events by 8 Percent More Than Trulicity in 13,000-Patient Diabetes Trial
-
JB Pharma Q1 Net Profit Surges 14 Percent to ₹202 Crore Revenue Hits ₹1094 Crore with 30 Percent EBITDA Margin
-
Trump Pressures 17 Pharma CEOs to Match US Drug Prices with Global Lows September 29 Deadline Set
-
Bayer Sets Aside $1.37 Billion for Roundup Lawsuits Raises 2025 Sales Forecast to €48 Billion
-
In October, the Chinese marine fuel market trended downward with fluctuations
-
China's urea market shows weak performance (8.4-8.8)
-
The Market Trend of Butadiene Rubber Weakens
-
$2.43 Billion Deal: Olin Buys Huntsman
-
Moldova Proposes Stricter Quality Standards for Edible Casein and Caseinates